Suma Koney, M.D.


Published on

Cardiac Care for the Cancer Survivor

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Suma Koney, M.D.

  1. 1. Cardiac Care for the Cancer Survivor Suma H. Konety, MD, MS Cardiovascular Division University of Minnesota
  2. 2. Overview• Cancer treatment related cardiotoxicity – what, when, how, who?• Strategies to prevent cardiac toxicity.• Role of cardiac imaging in screening.• Future directions to mitigate risk.
  3. 3. Current State• Long term cancer survivors are increasing.• Cancer treatment can lead to unintended and lasting damage to the cardiovascular system.• Many antineoplastic agents cause cardiotoxicity.• Broad clinical spectrum of cardiac problems.• The pathophysiology is not completely understood.• There is no clear consensus on how to treat cardiac dysfunction in cancer patients.
  4. 4. Cancer Therapies Implicated in Cardiovascular Complications• Chemotherapy agents • Radiation therapy – Anthracyclines – Mantle • Daunorubicin – Mediastinal • Doxorubicin – Cervical • Epirubicin – Supraclavicular • Idarubicin • Mitoxantrone – Left breast radiation – Tyrosine kinase inhibitors • Trastuzumab • Avastin • Sunitinib • Dasatinib – Alkylating Agents • Cyclophosphamides
  5. 5. Cardiovascular Complications From Cancer Therapy Chemotherapy Radiation therapy• Cardiomyopathy • Coronary heart disease – Asymptomatic • Valvular heart disease – Symptomatic • Pericardial disease• Arrhythmias • Vascular disease• Hypertension • Congestive heart failure• Coronary heart disease • Arrhythmias• Dyslipidemia
  6. 6. Signs and Symptoms Cancer Therapy Induced CardiomyopathySymptoms Signs• Shortness of breath • Jugular venous distension• Chest pain • Cardiac murmur• Palpitations • S3, S4• Swelling of the feet • Pericardial rub• Abdominal fullness • Rales, wheezes • Peripheral edema
  7. 7. Chemotherapy Induced Cardiomyopathy • LVEF <50% or a 10% drop in LVEF is widely accepted as LV dysfunction in the oncology community. • LV dysfunction could be symptomatic or asymptomatic. • LV dysfunction could manifest acutely or have a late onset and can also be chronic and progressive. Yeh ETH, et al. JACC 2009:53.
  8. 8. Pathophysiology of Anthracycline Cardiac Toxicities• Anthracyclines has been a mainstay of therapy for breast cancer, leukemia, lymphoma, sarcoma, etc..• Damages nuclear DNA, changes calcium handling and cellular contractility, suppresses factors that regulate cell survival and protein synthesis.• Serial imaging is the current screening strategy• Early detection and treatment could be lifesaving
  9. 9. Anthracycline-induced cardiomyopathy
  10. 10. CHF in Breast Cancer SurvivorsUsing the Surveillance, Epidemiology and End Results (SEER) Medicare database women aged 66 to70 treated with anthracycline compared with other chemotherapy had a 26% higher risk of CHF. Pinder MC, et al. JCO 2007;25(25):3808-3815.
  11. 11. Strategies For Prevention ofAnthracycline- induced CHF
  12. 12. Statins Protect Breast Cancer Patients From Heart Failure Using the Cleveland Clinic database women with breast cancer after treatment with anthracycline who received statin therapy compared to cancer controls not on statin had a 70% lower risk of incident CHF. Seicean S, et al. JACC 2012;60:2384-90.
  14. 14. Diagnostic Options Cancer Therapy Induced Cardiomyopathy• HOW – Imaging • Nuclear ventriculography • Echocardiography – 2D, 3D, strain, stress • Cardiac magnetic resonance • Vascular function – Biomarkers • NT pro-BNP • Troponin• WHO• WHEN
  15. 15. • Observational study of 42 patients with anthracyclines compared to 15 healthy controls• On cardiac MR - no myocardial edema or focal scar• Diffuse myocardial fibrosis was found in the anthracycline treated patients compared to controls• Implication - • Is DF a transition step from normal to irreversible damage? • Role of RAS modulators to reverse the remodeling process?
  16. 16. ACC/AHA Guidelines for Evaluation and Management of HF
  17. 17. Secondary Prevention Cancer Therapy Induced Cardiomyopathy• There is paucity of well-conducted RCTs that would provide the evidence to support pharmacological intervention.• Studies have failed to demonstrate clinically significant improvement in cardiac function in childhood cancer survivors.*• However, survivors treated with high dose (≥300 mg/m2) of anthracyclines benefited most from the intervention.*• In muscular dystrophy patients, there was survival benefit with afterload reduction.+ * Silber JH et al. J Clin Oncol: 22; 2004. + Connuck DM et al. Am Heart J: 155;2008.
  18. 18. Risk Factors For Chemotherapy Related Cardiac Toxicity COG LTFU Guidelines: 2008
  19. 19. Chemotherapy: Screening COG LTFU Guidelines: 2008
  20. 20. Radiation therapy• 294 patients w/ Hodgkins• >35 Gy radiation• Exercise stress test• Conventional risk factors were not consistently present in patients w/ CHD• 14% (n=40) had CHD, >50% coronary stenosis• More common >10 yr after radiation• Screening recommended 5-10 years after radiation
  21. 21. Radiation Therapy and Heart DiseaseIncreasing risk of death and coronary events in women treated with higher doses of RTand increased cardiac risk factors. Darby SC et al. NEJM: 368; 2013.
  22. 22. Risk Factors For Radiation Therapy Related Cardiac Toxicity COG LTFU Guidelines: 2008
  23. 23. Radiation Therapy: Screening COG LTFU Guidelines: 2008
  24. 24. Referral to the Cardiology• Subclinical abnormalities on screening evaluations – Left ventricular dysfunction LVEF <55% – Arrhythmias – QT interval prolongation• 5-10 years after chest radiation – > 40 Gy of chest radiation – > 30 Gy of chest radiation + anthracyclines• Isometric exercise program in any high risk patient – Patients involved in varsity team sports
  25. 25. Health Counseling• Heart health – Blood pressure (<140/90 mmHg), weight (BMI <25), cholesterol, glucose• Heart Healthy diet – Fresh fruits, vegetables, whole grains – Calories from fat <35% of total calories eaten each day – Limit saturated fat• Daily exercise – Aerobic exercise generally safe – Avoid intensive isometric exercises (heavy weight lifting, wrestling) – High repetition weight lifting using lighter weights safer• Dental Health• Tobacco cessation
  26. 26. Conclusions• It is clear that both the disease (cancer) and the treatment itself carry life threatening risk.• Variability on susceptibility to cardiac damage is not completely explained by clinical and demographic factors, suggesting genetic predisposition.• Pharmacogenomics is a promising strategy to minimize harm and maximize benefits.
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.